OasisLMS

Upon completion of this activity, a participant should be able to:
• Gain comprehensive insight into the WHO's objective for viral hepatitis elimination, including the essential components required for its
successful attainment.
• Discuss the challenges of managing hepatitis C virus infection in patients with hepatocellular carcinoma.
• Describe the latest advancements in the treatment landscape for chronic hepatitis B, focusing particularly on the INASL recent position statements on the prevention, diagnosis, and treatment of HBV infection.

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

While this activity will not be offering CE Credits, we are notifying you of our offerings.

Harrys Torres, MD, FAASLD
Research Grants: National Cancer Institute, Gilead Sciences, and Merck & Co., Inc

Carla Coffin, MD, FAASLD
Scientific Consultant/Advisor: Altimmune Pharmaceuticals, Roche
Research Grants: Gilead Sciences, GlaxoSmithKlein,  Janssen Investigator Initiated / Industry Partnered to the Canadian HBV Network

Madhumita Premukumar, MBBS, MD, DM
Nothing to Disclose

Rabha Dhiman, MD, DM, FACG, FRCP, FAASLD
Nothing to Disclose

Praveen Sharma, DM
Nothing to Disclose